Augmenting cancer care
Genomill is developing and enabling accessible top-tier cancer diagnostics. We are driving a global impact on healthcare with our unique technological innovation – Geno1™.
Reduced
cost
Increased
accuracy
Faster
turn-around-time
Geno1™
Driven by world-class research
Our Geno1™ technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and artificial intelligence.
It truly provides means for unprecedented scaling of liquid biopsies and beyond by tackling the three main drivers: cost, accuracy and turn-around-time.
Join our journey
We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1™ for out-licensing and are continuously looking for new long-term partnerships.
Join us in democratizing true game-changing technology!
Get in touch by emailing us at info@genomill.com!
Latest news
Genomeweb: Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing
NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming to broaden adoption of its Geno1 technology, a barcoding-based method that it believes can enhance sequencing accuracy and lower costs…
Genomill Health closes investment round to expand beta-testing with liquid biopsy players
Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive technology, focusing on efficient use of NGS (next generation sequencing) in liquid biopsies for cancer diagnostics.
